| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/GCC.20854 |
| P698 | PubMed publication ID | 21305640 |
| P50 | author | Wade S. Samowitz | Q112111709 |
| P2093 | author name string | Christine L Baker | |
| Larissa V Furtado | |||
| Cecily P Vaughn | |||
| Scott D Zobell | |||
| P2860 | cites work | KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 |
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Germline KRAS mutations cause Noonan syndrome | Q28297024 | ||
| Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications | Q33947050 | ||
| Sensitive sequencing method for KRAS mutation detection by Pyrosequencing | Q35789986 | ||
| Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy | Q36610301 | ||
| RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A | Q36730389 | ||
| High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients | Q37109358 | ||
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. | Q37330719 | ||
| Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer | Q37378581 | ||
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 | ||
| Biochemical characterization of a novel KRAS insertion mutation from a human leukemia | Q42806046 | ||
| KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial | Q43250046 | ||
| Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer | Q44834239 | ||
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab | Q46903224 | ||
| Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. | Q54081321 | ||
| PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients | Q61481236 | ||
| Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps | Q77647963 | ||
| Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone | Q81629286 | ||
| High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer | Q81643198 | ||
| P433 | issue | 5 | |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 307-312 | |
| P577 | publication date | 2011-02-08 | |
| P1433 | published in | Genes, Chromosomes and Cancer | Q5532697 |
| P1476 | title | Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. | |
| P478 | volume | 50 |
| Q52680663 | A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells. |
| Q40466906 | A case report of successful diagnosis of a pulmonary nodule by a survey of oncogenic mutations; primary lung carcinoma or pulmonary metastasis? |
| Q36089983 | A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens |
| Q41031884 | A pyrosequencing-based method to quantify genetic substitutions associated with resistance to succinate dehydrogenase inhibitor fungicides in Botrytis spp. populations |
| Q39211872 | A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: a model for qPCR testing without standard curves |
| Q36093324 | A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing |
| Q35368335 | A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer |
| Q33945376 | A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. |
| Q26748924 | Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer |
| Q33732199 | Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review |
| Q93052870 | Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population |
| Q51033838 | Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? |
| Q48010330 | Association between clinicopathological characteristics and RAS mutation in colorectal cancer |
| Q38932418 | Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer |
| Q91994664 | BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study |
| Q38194099 | BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma |
| Q34517338 | BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients |
| Q51014855 | BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. |
| Q48731798 | BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy |
| Q30458424 | BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies |
| Q54325213 | BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. |
| Q38222512 | Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer |
| Q64261433 | Biomarker concordance between primary colorectal cancer and its metastases |
| Q38217738 | Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer |
| Q41503593 | Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer |
| Q26766535 | Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS |
| Q61917173 | Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer |
| Q64091245 | Candidate genes and potential mechanisms for chemoradiotherapy sensitivity in locally advanced rectal cancer |
| Q85364773 | Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer |
| Q93200678 | Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review |
| Q104064604 | Clinical features and KRAS mutation in colorectal cancer with bone metastasis |
| Q37708040 | Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer |
| Q90304404 | Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study |
| Q41156932 | Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAFV600E Mutation |
| Q39722702 | Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases |
| Q39184305 | Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models. |
| Q89727321 | Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants |
| Q42229907 | Colorectal Cancer Screening: A Comprehensive Review to Recent Non-Invasive Methods |
| Q60929943 | Colorectal cancer vaccines: Tumor-associated antigens neoantigens |
| Q38255029 | Colorectal serrated pathway cancers and precursors |
| Q44193651 | Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. |
| Q58575063 | Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene |
| Q31096247 | Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma |
| Q92646445 | Correlation between clinicopathological features and KRAS, NRAS, and BRAF mutation status in Chinese colorectal cancer patients |
| Q26740067 | Current targeted therapies in the treatment of advanced colorectal cancer: a review |
| Q89717427 | DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation |
| Q39122119 | DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype |
| Q102152296 | Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations |
| Q29615778 | Detection of circulating tumor DNA in early- and late-stage human malignancies |
| Q38838631 | Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review |
| Q55473473 | Differences in gene mutations according to gender among patients with colorectal cancer. |
| Q36606380 | Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling |
| Q55024446 | Does Harvey-Ras gene expression lead to oral squamous cell carcinoma? A clinicopathological aspect. |
| Q48278060 | Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas. |
| Q33566687 | EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics |
| Q90248599 | Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases |
| Q47377842 | Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy |
| Q54949200 | Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study. |
| Q37534700 | GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers |
| Q33683680 | Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer |
| Q54362088 | Genetic mechanisms in interval colon cancers. |
| Q57567361 | Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry |
| Q92876951 | High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer |
| Q36238965 | How many diseases are colorectal cancer? |
| Q37298284 | Identification of HRAS as cancer-promoting gene in gastric carcinoma cell aggressiveness |
| Q38823554 | Immunogenicity of somatic mutations in human gastrointestinal cancers. |
| Q53227877 | Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types. |
| Q48070124 | Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test |
| Q35527097 | Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms |
| Q35061213 | Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma |
| Q55362851 | Immunotherapies: Exploiting the Immune System for Cancer Treatment. |
| Q57800147 | Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis |
| Q52677215 | Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. |
| Q54345735 | Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. |
| Q43215418 | K-ras Mutation in Colorectal Cancer, A Report from Southern Iran. |
| Q34346064 | KRAS and BRAF mutational status in colon cancer from Albanian patients |
| Q45764349 | KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort |
| Q54373305 | KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations? |
| Q37224269 | KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer |
| Q38391778 | KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at? |
| Q34269163 | KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer |
| Q40108385 | KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. |
| Q34375540 | Lynch syndrome-associated breast cancers do not overexpress chromosome 11-encoded mucins |
| Q24598640 | Markers of resistance to anti-EGFR therapy in colorectal cancer |
| Q35709696 | Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases |
| Q87156375 | Metastatic melanoma mimicking solitary fibrous tumor: report of two cases |
| Q37710556 | Molecular Testing for Gastrointestinal Cancer. |
| Q37708015 | Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. |
| Q37190124 | Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment |
| Q54334205 | Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. |
| Q52660142 | Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma. |
| Q54260718 | Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras. |
| Q37878380 | Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports |
| Q34365949 | Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. |
| Q90067743 | Mutated RAS: Targeting the "Untargetable" with T Cells |
| Q58707595 | Mutation Status and Immunohistochemical Correlation of , and in 260 Chinese Colorectal and Gastric Cancers |
| Q52582055 | Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. |
| Q37142999 | Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy |
| Q54339901 | Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group. |
| Q41614877 | Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma |
| Q28541288 | Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel |
| Q37231968 | Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer |
| Q34528276 | Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer. |
| Q40745198 | PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes |
| Q38580566 | Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus |
| Q59632229 | Predictive Values for Molecular Diagnostics: Converting Unknown Unknowns to Known Unknowns |
| Q90683727 | Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis |
| Q36396396 | Prognostic and predictive roles of KRAS mutation in colorectal cancer |
| Q98771735 | Progress in Neoantigen Targeted Cancer Immunotherapies |
| Q53216530 | RAS status in Korean patients with stage III and IV colorectal cancer. |
| Q50048719 | RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment |
| Q43061154 | RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers |
| Q34202697 | Ras in cancer and developmental diseases |
| Q35987390 | Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells |
| Q39140763 | Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer |
| Q90688967 | Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes |
| Q58783248 | Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017 |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q44995693 | Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. |
| Q39206525 | SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma. |
| Q53164323 | Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. |
| Q42361474 | Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits |
| Q34978610 | Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. |
| Q36800445 | Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation |
| Q30832820 | T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. |
| Q37223669 | Targeting neoantigens for cancer immunotherapy |
| Q90290671 | The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line |
| Q41972599 | The Presence of Mutations in the K-RAS Gene Does Not Affect Survival after Resection of Pulmonary Metastases from Colorectal Cancer |
| Q55461604 | The diagnostic role and clinical relevance of determination of BRAF status in brain tumors. |
| Q30414395 | The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors |
| Q38525475 | The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors |
| Q55233897 | The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. |
| Q35782746 | The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order |
| Q33768220 | The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. |
| Q33679614 | The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer |
| Q64062899 | Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing |
| Q36656389 | Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. |
| Q64059918 | and polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children |
| Q37680565 | mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. |
| Q37190094 | miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS |
Search more.